tradingkey.logo

BRIEF-Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery Of Semaglutide Via Ranipill HC

ReutersFeb 5, 2025 9:18 PM

- Rani Therapeutics Holdings Inc RANI.O:

  • RANI THERAPEUTICS ANNOUNCES PRECLINICAL DATA DEMONSTRATING SUCCESSFUL ORAL DELIVERY OF SEMAGLUTIDE VIA RANIPILL® HC

  • RANI THERAPEUTICS HOLDINGS INC - RT-116 WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS

  • RANI THERAPEUTICS HOLDINGS INC - PHASE 1 STUDY FOR RT-114 EXPECTED TO INITIATE IN 2025

Source text: ID:nGNX3fYhzr

Further company coverage: RANI.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI